Scinai Immunotherapeutics jumps as new CDMO agreement boosts contracted order book

By: Quiver PriceTracker

Posted: 3 hours ago / Oct. 13, 2026 2:52 p.m. UTC

SCNI

Scinai Immunotherapeutics Ltd. (SCNI) is up 9.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a new development and clinical manufacturing agreement that materially expands Scinai’s CDMO business. Investors also appear to be reacting to the larger contracted order base and the possibility of follow-on manufacturing work beyond the initial commitment.

Details:

Scinai announced on October 13, 2026 that its subsidiary signed a definitive agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company.

The deal includes about $5.1 million in committed base service fees tied to development and clinical manufacturing work, with revenue expected to contribute during 2026 and 2027 as work is performed.

The company said Committed Customer Orders rose to about $7.6 million after the agreement, up roughly 300% from year-end 2025 and more than double the level disclosed in mid-August 2026.

Management also outlined potential additional clinical manufacturing activity with an indicative uncommitted value of $5.85 million for late 2027 through the first half of 2028, which may be supporting bullish sentiment even though it is not yet contracted.

Sources:

Scinai, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive SCNI Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$SCNI Hedge Fund Activity

We have seen 8 institutional investors add shares of $SCNI stock to their portfolio, and 1 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARMISTICE CAPITAL, LLC added 35,942 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,078
VIRTU FINANCIAL LLC added 19,485 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,921
STONEX GROUP INC. added 13,092 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,307
HRT FINANCIAL LP added 12,088 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,053
CAPTRUST FINANCIAL ADVISORS added 12,035 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,040
RHUMBLINE ADVISERS added 11,635 shares (+619.5%) to their portfolio in Q2 2026, for an estimated $2,939
XTX TOPCO LTD removed 7,277 shares (-30.3%) from their portfolio in Q2 2026, for an estimated $1,838

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.